Low-value approvals and high prices might incentivize ineffective drug development

Vinay Prasad; Christopher McCabe; Sham Mailankody

doi:10.1038/s41571-018-0030-2

Low-value approvals and high prices might incentivize ineffective drug development

Vinay Prasad, Christopher McCabe, Sham Mailankody

Knight Cancer Institute

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Drug regulators’ acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.

Original language	English (US)
Pages (from-to)	1-2
Number of pages	2
Journal	Nature Reviews Clinical Oncology
DOIs	https://doi.org/10.1038/s41571-018-0030-2
State	Accepted/In press - May 14 2018

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/s41571-018-0030-2

Fingerprint Dive into the research topics of 'Low-value approvals and high prices might incentivize ineffective drug development'. Together they form a unique fingerprint.

Cite this

Prasad, V., McCabe, C., & Mailankody, S. (Accepted/In press). Low-value approvals and high prices might incentivize ineffective drug development. Nature Reviews Clinical Oncology, 1-2. https://doi.org/10.1038/s41571-018-0030-2

@article{f68d94af1afa4dccb8398e7f8f451b94,

title = "Low-value approvals and high prices might incentivize ineffective drug development",

abstract = "Drug regulators{\textquoteright} acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.",

author = "Vinay Prasad and Christopher McCabe and Sham Mailankody",

year = "2018",

month = may,

day = "14",

doi = "10.1038/s41571-018-0030-2",

language = "English (US)",

pages = "1--2",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Low-value approvals and high prices might incentivize ineffective drug development

AU - Prasad, Vinay

AU - McCabe, Christopher

AU - Mailankody, Sham

PY - 2018/5/14

Y1 - 2018/5/14

N2 - Drug regulators’ acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.

AB - Drug regulators’ acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.

UR - http://www.scopus.com/inward/record.url?scp=85047011186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047011186&partnerID=8YFLogxK

U2 - 10.1038/s41571-018-0030-2

DO - 10.1038/s41571-018-0030-2

M3 - Article

C2 - 29760505

AN - SCOPUS:85047011186

SP - 1

EP - 2

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -